|
(ÁÖ)Á¦´º¿ø»çÀ̾𽺠|
RAÁ÷¹« °æ·Â»ç¿ø ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
2³â¡è |
04.02 |
03.22 |
|
|
´º·ÎÇÍ ÁÖ½Äȸ»ç |
ÇØ¿Ü¿µ¾÷
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¹«¿ª/ÇØ¿Ü¿µ¾÷/Åë¹ø¿ª |
3³â¡è |
ä¿ë½Ã |
|
|
|
Novotech |
Pharmacovigilance Associate (Snr)_Korean Speaker Only
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
1³â¡è |
ä¿ë½Ã |
03.13 |
|
|
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ) |
Environmental Health & Safety (EHS) Advisor (¾ÈÀü°ü¸®ÀÚ)
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¼ö½Ãä¿ë |
1³â¡è |
ä¿ë½Ã |
02.23 |
|
|
¼¼ºñ¾ÆÄÚ¸®¾Æ À¯ÇÑȸ»ç |
[Sebia KOrea Ltd.] Territory Manager
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
5³â¡è |
ä¿ë½Ã |
02.19 |
|
|
¾Ëº¸Á¨ ÄÚ¸®¾Æ ÁÖ½Äȸ»ç |
[¾Ëº¸Á¨ÄÚ¸®¾Æ] OPERATION QA Manager
°æ±â ȼº½Ã | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
5³â¡è |
ä¿ë½Ã |
02.20 |
|
|
Alvogen Korea |
[¾Ëº¸Á¨ÄÚ¸®¾Æ] Á¦Á¶/Ç°Áú°ü¸® ¾à»ç
°æ±â ȼº½Ã, Ãæ³² °øÁֽà | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
02.15 |
|
|
Novotech |
[³ëº¸ÅØ] Senior CRA ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
3³â¡è |
ä¿ë½Ã |
02.15 |
|
|
Novotech |
[³ëº¸ÅØ] Associate Director, Regulatory Operations ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
10³â¡è |
ä¿ë½Ã |
02.26 |
|
|
Novotech |
[Novotech] Business Development Manager ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ý¸í°øÇÐ/¹ÙÀÌ¿À ¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
03.13 |
|
|
Janssen |
[Janssen] Project Manager (Local Trial Manager)
¼¿ï ¿ë»ê±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
2³â¡è |
ä¿ë½Ã |
01.29 |
|
|
ºñ¾¾¿ùµåÁ¦¾à |
2024³â 2ºÐ±â ¿µ¾÷¸¶ÄÉÆú»ºÎ(¸¶ÄÉÆÃPM/¿µ¾÷MR) ä¿ë
Àü±¹ ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
°æ·Â¹«°ü |
04.04 |
03.25 |
|
|
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ) |
[±Û·Î¹ú Á¦¾à»ç] Therapy Area Manager, Rare Disease & Oth
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
10³â¡è |
ä¿ë½Ã |
01.12 |
|
|
ÁÖ½Äȸ»ç ÇÑâ¸Þµñ |
(ÁÖ)ÇÑâ¸Þµñ Ç°ÁúÆÀ ä¿ë °ø°í
Ãæ³² ¾Æ»ê½Ã | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
5³â¡è |
ä¿ë½Ã |
02.14 |
|
|
¿¡À̽º¸ÞµðÄ®(ÁÖ) |
ÀÇ·á±â±â ¿¬±¸¿ø(±â±¸ ¼³°è) °æ·Â
¼¿ï °µ¿±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CAD |
1³â¡è |
ä¿ë½Ã |
03.27 |
|